ALCAM and CD6--multiple sclerosis risk factors.
M Wagner1, M Bilinska2, A Pokryszko-Dragan2
1Laboratory of Immunogenetics and Tissue Immunology, Department of Clinical Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland.
Journal of Neuroimmunology
|September 14, 2014
Summary
The ALCAM gene is linked to multiple sclerosis (MS) risk and progression. CD6 gene variations and lower mRNA expression are also associated with MS, suggesting a role in disease pathogenesis.
Area of Science:
- Neuroimmunology
- Genetics
Background:
- Leukocyte transmigration across the blood-brain barrier is crucial in multiple sclerosis (MS) pathogenesis.
- Cell adhesion molecules like Activated Leukocyte Cell Adhesion Molecule (ALCAM) and its receptor CD6 are implicated in this process.
Purpose of the Study:
- To investigate the association of ALCAM and CD6 gene polymorphisms and CD6 mRNA expression with multiple sclerosis (MS).
- To confirm previous findings on the ALCAM gene's role in MS risk, development, and progression.
Main Methods:
- Genotyping for ALCAM and CD6 gene polymorphisms, including rs12360861.
- Quantitative analysis of CD6 mRNA expression levels in MS patients and healthy controls.
Main Results:
- The ALCAM gene association with MS risk, development, and progression was confirmed.
- Specific ALCAM gene polymorphisms (rs12360861) showed a significantly lower risk for individuals with the AA genotype compared to GG (OR=0.34).
- Lower CD6 mRNA expression was observed in MS patients compared to healthy individuals (p=0.002).
Conclusions:
- Both ALCAM and CD6 play significant roles in multiple sclerosis (MS) pathogenesis.
- CD6 gene polymorphisms and reduced mRNA expression are associated with MS, highlighting its importance beyond ALCAM binding.
More Related Videos
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
9
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
9
01:29Alzheimer Disease l: Introduction
13
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
13
01:23Alzheimer Disease ll: Pathophysiology
16
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
16
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Autoimmune Disorders
2.3K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.3K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K